INNOVA CAPTAB
|
INNOVA CAPTAB Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 24.63 | 22.41 | 16.49 | 14.16 | 531.54 |
| CEPS(Rs) | 32.52 | 26.74 | 19.28 | 16.46 | 14.89 |
| DPS(Rs) | 2.00 | - | - | - | - |
| Book NAV/Share(Rs) | 190.61 | 167.66 | 145.20 | 57.61 | 1,738.38 |
| Tax Rate(%) | 25.15 | 25.00 | 27.16 | 25.97 | 25.39 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.96 | 14.71 | 14.25 | 12.09 | 11.88 |
| EBIT Margin(%) | 12.37 | 13.70 | 13.93 | 11.89 | 11.31 |
| Pre Tax Margin(%) | 11.35 | 13.51 | 11.95 | 9.76 | 10.60 |
| PAT Margin (%) | 8.49 | 10.13 | 8.71 | 7.23 | 7.91 |
| Cash Profit Margin (%) | 11.22 | 12.09 | 10.18 | 8.41 | 8.84 |
| Performance Ratios | |||||
| ROA(%) | 8.17 | 8.78 | 9.08 | 9.99 | 12.58 |
| ROE(%) | 13.75 | 14.33 | 17.04 | 28.02 | 36.19 |
| ROCE(%) | 15.04 | 14.65 | 19.06 | 24.34 | 30.64 |
| Asset Turnover(x) | 0.96 | 0.87 | 1.04 | 1.38 | 1.59 |
| Sales/Fixed Asset(x) | 1.79 | 1.94 | 3.48 | 4.46 | 5.17 |
| Working Capital/Sales(x) | 3.87 | 3.69 | 3.45 | 5.70 | 9.56 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.56 | 0.52 | 0.29 | 0.22 | 0.19 |
| Receivable days | 84.59 | 89.43 | 93.25 | 92.78 | 79.30 |
| Inventory Days | 54.04 | 50.76 | 44.01 | 47.70 | 49.63 |
| Payable days | 114.83 | 108.88 | 106.52 | 100.16 | 88.60 |
| Valuation Parameters | |||||
| PER(x) | 27.91 | 39.15 | 27.18 | - | - |
| PCE(x) | 21.14 | 32.81 | 23.25 | - | - |
| Price/Book(x) | 3.61 | 5.23 | 3.09 | - | - |
| Yield(%) | 0.29 | - | - | - | - |
| EV/Net Sales(x) | 2.62 | 4.25 | 2.52 | 0.29 | 0.26 |
| EV/Core EBITDA(x) | 17.07 | 26.69 | 16.29 | 2.15 | 2.10 |
| EV/EBIT(x) | 20.82 | 30.50 | 18.01 | 2.36 | 2.27 |
| EV/CE(x) | 2.98 | 4.08 | 2.54 | 0.52 | 0.34 |
| M Cap / Sales | 2.41 | 4.04 | 2.37 | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 31.06 | 15.02 | 16.72 | 15.72 | 94.94 |
| Core EBITDA Growth(%) | 26.31 | 18.72 | 35.90 | 24.21 | 77.06 |
| EBIT Growth(%) | 18.30 | 14.86 | 35.09 | 22.28 | 81.81 |
| PAT Growth(%) | 9.87 | 35.95 | 38.84 | 6.26 | 85.37 |
| EPS Growth(%) | 9.87 | 35.95 | 16.46 | -97.34 | 85.30 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.31 | 0.35 | 0.29 | 0.85 | 0.95 |
| Current Ratio(x) | 1.83 | 1.91 | 2.07 | 1.59 | 1.27 |
| Quick Ratio(x) | 1.28 | 1.36 | 1.58 | 1.17 | 0.86 |
| Interest Cover(x) | 12.14 | 72.11 | 7.04 | 5.60 | 16.09 |
| Total Debt/Mcap(x) | 0.09 | 0.07 | 0.09 | - | - |
Compare Financial Ratios of peers of INNOVA CAPTAB
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INNOVA CAPTAB | ₹4,932.4 Cr | 0.2% | -1.5% | -0.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹427,933.0 Cr | -0.7% | -3.6% | 6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,833.0 Cr | 1.1% | -1.2% | -0.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,549.0 Cr | 1.6% | 1.4% | 36.7% | Stock Analytics | |
| CIPLA | ₹113,155.0 Cr | 0.7% | 2.6% | -4.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,652.0 Cr | -0.9% | -2.5% | 1.2% | Stock Analytics | |
INNOVA CAPTAB Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INNOVA CAPTAB | 0.2% |
-1.5% |
-0.6% |
| SENSEX | -0.7% |
-3.6% |
-9.1% |
You may also like the below Video Courses
